Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 14Glioblastoma 6Neoplasms 4Lymphoma, Non-Hodgkin 4Breast Neoplasms 4Testicular Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Neoplasm Metastasis 3Meningeal Carcinomatosis 3Lymphoma 3Glioma 3Burkitt Lymphoma 3Vomiting 2Testicular Germ Cell Tumor 2Sezary Syndrome 2Recurrence 2Radiation Injuries 2Primary Myelofibrosis 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Oligodendroglioma 2Nausea 2Myeloproliferative Disorders 2Mycosis Fungoides 2Multiple Myeloma 2Melanoma 2Medulloblastoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2

Interventions

Temozolomide 1Microarray Analysis 1Dexamethasone 1DNA Methylation 1Calcium Dobesilate 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Basophil × Dexamethasone × CNS × Clear all
NCT01088763 2014-11-05

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
129 enrolled
CNSEndocrineLymphoidOther hematologic neoplasmSarcoma

Familial ependymoma, Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Astrocytoma, Burkitt Lymphoma, Medulloblastoma, Oligodendroglioma, Pituitary Neoplasms, Recurrence, Spinal Cord Neoplasms, Prolactinoma, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Rhabdoid Tumor, Optic Nerve Glioma, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡